Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Ovid Therapeutics Inc.NASDAQ: OVID
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $35K fell 75.2% year over year, behind the -72.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 105.9% from the prior quarter. Over 3 fiscal years it compounded at -41.8% a year.
Context
- Depreciation & amortization amounted to 3.8% of revenue in FY2025, down 104.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -75.2% toward the trailing-twelve-month pace of -72.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 273K USD
- Year-over-year change
- -55.5%
- 4-year CAGR
- +3.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 273K | -55.5% |
| FY2024 | 2024-12-31 | 613K | -61.6% |
| FY2023 | 2023-12-31 | 1.6M | +15.6% |
| FY2022 | 2022-12-31 | 1.38M | +483.0% |
| FY2021 | 2021-12-31 | 237K | — |
Depreciation & Amortization vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 depreciation & amortization of $168K is the smallest of the 11 companies compared; the peer median is $3.62M.
- Its year-over-year change of -72.2% is the lowest of 11, against a peer median of +0.8%.
- Depreciation & amortization amounts to 2.4% of revenue for OVID, versus a peer median of 11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $28.32M | +126.8% | +13.8% | 35.5% | |
| LTM Mar 2026 | $13.62M | -61.8% | +24.3% | 2.0% | |
| LTM Mar 2026 | $10.18M | +0.4% | +20.7% | — | |
| LTM Mar 2026 | $8.15M | -5.8% | -4.3% | 11.4% | |
| LTM Mar 2026 | $3.62M | +20.6% | -8.0% | 24.9% | |
| LTM Mar 2026 | $3.61M | -20.6% | -13.1% | 9.9% | |
| LTM Mar 2026 | $3.22M | +1.1% | -1.1% | — | |
| LTM Mar 2026 | $2.28M | +9.0% | +4.6% | 7.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.99M | -1.7% | -30.8% | — |
| LTM Jun 2026 | $1.17M | +1.1% | -0.8% | 21.3% | |
| LTM Mar 2026 | $168K | -72.2% | -41.8% | 2.4% | |
| Peer median (excluding OVID) | $3.62M | +0.8% | -1.0% | 11.4% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 119.84M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Depreciation & Amortization | 237K | 1.38M | 1.6M | 613K | 273K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 6.56M | 7.29M | 6.28M | 4.81M |
| Change in Working Capital | (16.81M) | (8.23M) | 2.39M | (150K) | (4.1M) |
| Accounts Receivables | 141.76K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.7M | (5.17M) | 1.75M | (512K) | (1.23M) |
| Other Working Capital | (18.66M) | (3.06M) | 635.51K | 362K | (2.87M) |
| Other Non-Cash Items | 15.35M | (764.94K) | (4.71M) | (36.26M) | (21.9M) |
| Operating Cash Flow | 118.61M | (55.23M) | (45.78M) | (55.96M) | (38.33M) |
| Capital Expenditures | (189.41K) | (1.42M) | (137.46K) | (71K) | 0 |
| Acquisitions (Net) | (1.63M) | (2.5M) | (10M) | 0 | 0 |
| Purchases of Investments | (1.63M) | (172.96M) | (112.44M) | (73.25M) | (91.85M) |
| Sales of Investments | 0 | 90M | 120M | 128M | 42M |
| Other Investing Activities | (5.4K) | (1M) | (97.15K) | (89K) | 0 |
| Investing Cash Flow | (1.82M) | (87.88M) | (2.58M) | 54.59M | (49.85M) |
| Debt Repayment | 0 | 0 | 30M | 0 | 0 |
| Common Stock Issued | 925.4K | 180.66K | 535.2K | 622K | 75.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (21.31K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 904.08K | 180.66K | 30.54M | 622K | 75.21M |
| Effect of Forex Changes | (1.93M) | 0 | 0 | 0 | (167K) |
| Net Change in Cash | 115.76M | (142.93M) | (17.83M) | (740K) | (13.15M) |
| Free Cash Flow | 118.42M | (56.65M) | (45.92M) | (56.03M) | (38.33M) |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.